Science and Research

Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021

  • Evans, L.
  • Rhodes, A.
  • Alhazzani, W.
  • Antonelli, M.
  • Coopersmith, C. M.
  • French, C.
  • Machado, F. R.
  • McIntyre, L.
  • Ostermann, M.
  • Prescott, H. C.
  • Schorr, C.
  • Simpson, S.
  • Wiersinga, W. J.
  • Alshamsi, F.
  • Angus, D. C.
  • Arabi, Y.
  • Azevedo, L.
  • Beale, R.
  • Beilman, G.
  • Belley-Cote, E.
  • Burry, L.
  • Cecconi, M.
  • Centofanti, J.
  • Coz Yataco, A.
  • De Waele, J.
  • Dellinger, R. P.
  • Doi, K.
  • Du, B.
  • Estenssoro, E.
  • Ferrer, R.
  • Gomersall, C.
  • Hodgson, C.
  • Møller, M. H.
  • Iwashyna, T.
  • Jacob, S.
  • Kleinpell, R.
  • Klompas, M.
  • Koh, Y.
  • Kumar, A.
  • Kwizera, A.
  • Lobo, S.
  • Masur, H.
  • McGloughlin, S.
  • Mehta, S.
  • Mehta, Y.
  • Mer, M.
  • Nunnally, M.
  • Oczkowski, S.
  • Osborn, T.
  • Papathanassoglou, E.
  • Perner, A.
  • Puskarich, M.
  • Roberts, J.
  • Schweickert, W.
  • Seckel, M.
  • Sevransky, J.
  • Sprung, C. L.
  • Welte, T.
  • Zimmerman, J.
  • Levy, M.

Keywords

  • Adults
  • Evidence based medicine
  • Guidelines
  • Sepsis
  • Septic shock
  • Society and is the chair of the guidelines in intensive care, development and
  • evaluation (GUIDE) Group, McMaster University Canada. Dr. Antonelli received funding
  • from GE, Toray-Estor, Baxter, Pfizer, Orion, Maquet, and Fisher and Paykel
  • he was
  • on the board of Baxter and Pfizer, and is a member of the executive committee and
  • past president of Società Italiana di Anestesia Rianimazione e Terapia Intensiva
  • (SIAARTI). Dr. French contributed to the ANZICS Guidelines and the National COVID-19
  • Guidelines. Dr. Machado is a member of the Executive Committee for the Basics Study
  • (for which Baxter provided the drugs and logistics) and AMIB. Dr. McIntyre is a
  • member of the Canadian Critical Care Society and serves on the Surviving Sepsis
  • Campaign Steering Committee. Dr. Ostermann is a council member of the Intensive Care
  • Society UK and member of the Renal Association UK and World Sepsis Alliance. Dr.
  • Prescott is a member of the ATS Critical Care Program Committee. Dr. Simpson is the
  • president-elect and Chair of CHEST, is a member of the board of directors and
  • medical director of Sepsis Alliance, and Chair of the Sepsis Institute Advisory
  • Board. Dr. Wiersinga is a member of ISF, ESCMID, and SWAB. Dr. Angus received
  • funding from Ferring Pharmaceuticals, Inc and ALung Technologies, Inc. Dr. Beale
  • provides consultancy services for Philips Healthcare with his time billed by his
  • institution. Dr. Beilman is the president of the Surgical Infection Society. Dr.
  • Belley-Cote received grants from Roche and Bayer and is a panel member on the Saudi
  • Critical Care Society COVID-19 Thrombosis Guidelines. Dr. Cecconi is a consultant
  • for Edwards Lifesciences, Cheetah Medical, and Directed Systems and is President of
  • the European Society of Intensive Care Medicine. Dr. Coz is a board member of the
  • American College of Chest Physicians. Dr. De Waele consulted for Accelerate, Bayer,
  • Grifols, Pfizer, and MSD with all honoraria paid to Ghent University
  • he is a Senior
  • Clinical Investigator with the Research Foundation Flanders. Dr. Dellinger serves as
  • an expert witness on occasional medical legal case reviews. Dr. Doi is a member of
  • the Japanese Society of Intensive Care Medicine. Dr. Du is a member of the Chinese
  • Society of Critical Care Medicine and the Chinese College of Intensive Care
  • Medicine. Dr. Ferrer received funding from Grifols, MSD, Pfizer, Shionogi, Toray,
  • Jafron, and Cytosorbents
  • he is a member of SEMICYUC. Dr. Gomersall is a member of
  • an educational subgroup of the International Forum of Acute Care Trialists. Dr.
  • Hodgson is a member of the Australian National Health and Medical Research Council
  • guidelines (COVID-19) and leading funded trials in early rehabilitation and ECMO.
  • Dr. Møller contributed to guideline work for DASAIM, SSAI, GUIDE, and ESA. Dr.
  • Iwashyna is a member of the ATS, the NIH, and an informal (unincorporated)
  • organization called the Critical and Acute Illness Recovery Organization. Dr. Jacob
  • co-directs the African Research Collaboration on Sepsis (ARCS, funded by UK National
  • Institute for Health Research, sponsored by Liverpool School of Tropical Medicine),
  • he is Secretary General for the African Sepsis Alliance, and is a technical expert
  • for the World Health Organization panels. Dr. Kleinpell is a board member of the
  • World Federation of Intensive and Critical Care, American Nurses Credentialing
  • Center, and the Tennessee Nurses Association Political Action Committee. Dr. Klompas
  • received funding from Up-to-Date
  • he is a member of the guidelines committees of the
  • Infectious Disease Society of America (IDSA) and Society of Healthcare
  • Epidemiologists of America (SHEA). Dr. Koh is a member of The Korean Society of
  • Critical Care Medicine, The Korean Academy of Tuberculosis and Respiratory Diseases,
  • The Korean Society of Medical Ethics, and the Asia Ventilation Forum. Dr. Kumar
  • served as an expert witness regarding a lethal dose of narcotics. Dr. Kwizera is
  • president of the Intensive Care Society of Uganda and PRO for the Association of
  • Anesthesiologists of Uganda. Dr. Lobo received funding from Pfizer, MSD, Edwards,
  • and Nestle
  • she is the principal investigator in new antibiotics research led by
  • CROs/industry
  • she is a member of the AMIB Executive Board and was elected president
  • for 2020-2021. Dr. McGloughlin is a member of ANZICS (Australian New Zealand
  • Intensive Care Society). Dr. Mehta participated in two non-interventional studies by
  • ISCCM-Hermes and Indicaps. Dr. Mer has been an invited speaker for educational talks
  • in industry-sponsored symposia for which honoraria was received
  • he is the current
  • Vice President of the Southern African Society of Thrombosis and Haemostasis
  • (SASTH), and is involved in annual congress organization
  • he is an invited author of
  • the Global guidelines for the diagnosis and management of mucormycosis: an
  • initiative of the European Confederation of Medical Mycology in cooperation with the
  • Mycoses Study Group Education and Research Consortium. Dr. Nunnally is the treas-
  • urer of SOCCA, committee member of ASA, NYSSA, IARS, AUA, and SAAAPM and serves on
  • the American College of Critical Care Medicine Board of Regents. Dr. Oczkowski is a
  • member of the European Respiratory Society, and contributed to the High Flow Nasal
  • Cannula Guidelines, the Non-Invasive Ventilation in COPD Guidelines. Dr. Osborn
  • received funding from Viven Inc, Inflammatrix, Beckman, and the Foundation for
  • Barnes Jewish Hospital
  • she is on the advisory board for Beckman, Inflammatix, and
  • Viven
  • she is a member of the American College of Emergency Physicians, American
  • College of Chest Physicians, American Medical Association, Society of Academic
  • Emergency Medicine, and American Academy of Emergency Physicians
  • she served as an
  • expert witness in a case related to viral as compared to bacterial sepsis. Dr.
  • Papathanassoglou is a member of the World Federation of Critical Care Nurses (Editor
  • of Journal) and the Canadian Association of Critical Care Nurses. Dr. Perner
  • received a re- search grant from Pfizer Denmark. Dr. Puskarich is the co-inven- tor
  • of a patent to assess L0carnitine drug responsiveness in sepsis (USPO 10330685)
  • he
  • is a member of the Society for Academic Emergency Medicine, American College of
  • Emergency Physicians (ACEP)
  • he was invited to a recently gathered ACEP early sepsis
  • treatment policy task force asked to develop spe- cialty recommendations for early
  • sepsis treatment. Dr. Roberts received funding from MSD, The Medicines Company,
  • Cardeas Pharma, Biomerieux, QPEX, Cipla, and Pfizer
  • he consulted for MSD, QPEX,
  • Discuva Ltd, Accelerate Diagnostics, Bayer, Biomerieux, UptoDate, and Australian
  • Therapeutic Guidelines
  • he is a member of the Society of Hospital Pharmacists of
  • Australia Leadership Committees for Critical Care and Infectious Diseases and the
  • Lead of Sepsis Working group for the International Society of Anti-infective
  • Chemotherapy. Dr. Schweickert is a paid consultant to the American College of
  • Physicians (last performed in Spring, 2019). Dr. Seckel volunteers for AACN and is a
  • paid consultant to revise online Critical Care Orientation. Dr. Sevransky received
  • funding from the Marcus Foundation- PI VICTAS Trial and serves on the American
  • College of Critical Care Medicine Board of Regents. Dr. Welte received funding from
  • Astellas, AstraZeneca, Boehringer, Basilea, Bayer, Berlin-Chemie, Grifols,
  • Infectopharm, Mundipharma, MSD, Novartis, Pfizer, DFG, EU, BMBF, and Insmed
  • he is
  • on the advisory board for AstraZeneca, Boehringer, Bayer, Gilead, GSK, Insmed,
  • Novartis, Pfizer, Roche
  • he is a member of the European Respiratory Society, German
  • Society of Pneumology, and Paul Ehrlich Gesellschaft. Dr. Zimmerman is a member of
  • the ACP, AACP, and WFPICCS. Dr. Levy is a legal consultant for a few cases involving
  • sepsis and serves as co-chair of the Surviving Sepsis Campaign Steering Committee.
  • The remaining authors have disclosed that they do not have any potential conflicts
  • of interest.
Publication details
DOI: 10.1007/s00134-021-06506-y
Journal: Intensive Care Med
Pages: 1-67 
Work Type: Original
Location: BREATH
Disease Area: General Lung and Other
Partner / Member: MHH
Access-Number: 34599691

DZL Engagements

chevron-down